NEONIPIGA

1. 01

   Organ preservation is compelling for selected responders, but clinical response does not settle the need for surgery

   Sample finding · free

   An X-thread author asked how to specify a complete clinical response and plan surveillance for a possible watch-and-wait pathway in dMMR gastric or gastroesophageal-junction cancer.

   Source: X thread, 2022-08-17 · paraphrased; the full report links the source

2. 02

   Immunotherapy incorporation attracts support; chemotherapy omission and the preferred combination remain contested

3. 03

   Dual blockade's response appeal is limited by immune toxicity, while monotherapy remains a disputed alternative

   Context for these views, not raised in the commentary cited above. The trial publication reports: Neoadjuvant therapy-related grade 3/4 adverse events occurred in six patients (19%). The rate of surgical morbidity (Clavien-Dindo classification) was 55% (one postoperative death occurred).

4. 04

   High pCR is persuasive biological activity, not a demonstrated comparative survival advantage

5. 05

   After resection, clinicians separate perioperative immunotherapy from an unresolved adjuvant-only decision

6. 06

   Early tumor-specific testing and confirmation—not presumed MSI or a single positive biopsy—shape treatment choices

7. 07

   Surgery alone remains a conditional choice when downstaging is unnecessary or immediate local control matters

8. 08

   Funding and approval boundaries alter treatment delivered, even when clinicians favor immunotherapy

9. 09

   Radiation's role is disputed, with systemic-control arguments and selective exceptions kept distinct

10. 10

    For chemotherapy-plus-immunotherapy alternatives, PD-L1-negative disease prompts genuine disagreement about withholding treatment

11. 11

    Treatment duration and intensity are negotiated around response, postoperative recovery and tolerability

12. 12

    Organ preservation requires a surveillance-and-salvage system; ctDNA and patient support do not remove its limits

    Sample finding · free

    A guest in a YouTube discussion asked who is represented in the evidence and databases supporting circulating tumor DNA and RNA sequencing tests, and whether measurements are comparable across ancestry groups and disease types.

    Source: YouTube video, 2026-02-09 · paraphrased; the full report links the source

The full report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified claims with exact source passages.

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

2022-01-20 → 2026-09-28

Cited window

2022-01-20 → 2026-09-28

Retrieved

2026-10-08

Title

Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma: An Open-label GERCOR Phase II Study

Registry

NCT04006262

Study IDs

NEONIPIGA - D18-02

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborators

Bristol-Myers Squibb

Design

Phase 2 · interventional, na, single group, phase2

Status

Active not recruiting

Enrollment

32 estimated

Start

2019-10-23 actual

Primary completion

2025-10 estimated

Primary endpoint

Complete pathological response (cPRR) rate

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
• –1 matching source (1 podcast) could not be read and is not included.
• –For 4 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –16 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
• –2 further source limits are recorded in the machine-readable scope of this record.
• –The reviewed commentary comes from 68 retained sources, not 68 independent clinicians. Some recordings appear in more than one publication format, and several posts repeat the same study summary; repetition should not be interpreted as independent agreement.
• –Some public discussions could not be reviewed, and searches focused on the trial identifier and indexed trial names. Unnamed references and unusual transcriptions may therefore be absent, limiting claims about the breadth of the conversation.
• –Several recordings rely on the available written transcript rather than a separately checked recording. Some passages establish no speaker name, or only a first name; adjacent named comments do not establish who voiced those passages.
• –Study names, regimens and numerical descriptions sometimes differ between accounts or remain unclear. They are retained as what the speaker reported, not reconciled into corrected clinical facts. Thomas Samaille's reported pCR figure, for example, differs from the verified publication result.
• –Guideline, approval and reimbursement statements describe the speaker's setting and the evidence available during that discussion. They do not establish current global availability, and publication dates are not automatically session or readout dates.
• –NEONIPIGA's single-arm phase II context and the surgical pCR denominator limit comparative conclusions. Other-study comparisons and individual experiences do not establish superiority, equivalent efficacy or a survival benefit from omitting chemotherapy or surgery.
• –Allan Pereira's posts are attributable to the named author, but his clinical role is explicitly unresolved in the supplied professional context. His interpretations are retained as attributed commentary, not additional verification of clinical practice.
• –The report preserves views from different timepoints and clinical settings. Apparent differences between a clinician's comments do not, by themselves, establish a change of mind.

How reports are built and checked: Methods.

Last checked Oct 8, 2026. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch. No corrections.

release 791593395914ae13f346c571216464187f6abd57d1363682872c5c3f69c36118

The same record as JSON or Markdown, or through the Erudio MCP server.

curl https://www.erudio.com/reports/neonipiga-nct04006262.json
curl https://www.erudio.com/reports/neonipiga-nct04006262.md

# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "neonipiga-04006262" })